IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Stefan Golz, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP2004/010383

Title: Diagnostics and Therapeutics for Diseases Associated with G-Protein

Coupled Receptor ADIPOR2 (ADIPOR2)

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY 37 C.F.R. 1.97(b)(2)

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying form(s) PTO/SB/08A-B [substitute for form 1449/PTO].

A copy of the International Search Report prepared by the European Patent Office is also enclosed under 37 CFR 1.492(b)(3).

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Susan M. Pellegrino Reg. No.: 48,972

Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation 400 Morgan Lane West Haven, CT 06516 Telephone: (203) 812-6450

Facsimile: (203) 812-6459



PTO/SB/08A (07-05) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substit	ute for form 1449/P	то		Complete if Known		
				Application Number	[to be assigned]	
INIC		ON DI	SCLOSURE	Filing Date		
				First Named Inventor	Stefan Golz	
ST			APPLICANT	Art Unit		
	(Use as man	y sheets as	necessary)	Examiner Name		
 Shoot	1	of	2	Attorney Docket Number	I A A 36 902	

U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code ^{2 (# known)}			rigures Appear	
		US-				
		US-		***************************************	The second secon	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-			1	

			IGN PATENT DOCU			
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
miliais	NO.	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document		T ⁶
	F1	WO 2004/061108 A1	22-07-2004	Center for Advanced So	ience and	
				Technology Incubation,	Ltd.	
	F2	WO 2004/063711 A2	29-07-2004	Beth Israel Deaconess	Medical Center	
	F3	WO 02/072149 A1	19-09-2002	Oklahoma Medical Res	earch Foundation	
						Г

Examiner	Date	
Signature	Considered	
o ignature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.usoto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

IAP9 Rec'd PCT/PTO 2 0 MAR 2006

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
atent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
				Application Number	[to be assigned]	
INFO	PRMATIC	ON DIS	CLOSURE	Filing Date		
STATEMENT BY APPLICANT				First Named Inventor	Stefan GOLZ	
	(Use as many			Art Unit		
	(Ose as many	sneets as n	ecessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	Le A 36 902	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials* Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the article (when appropriate)						
	R1	Yamauchi, T., et al., "Cloning of Adiponectin Receptors that Mediate Antidiabetic Metabolic Effects", Nature, 423: 762-769 (June 2003)				
	R2	Yamauchi, T., et al., "The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity", Nature Medicine, 7(8): 941-946 (August 2001)				

Examiner	Date
Signature	Considered
ACMANIA CO. L. C.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.